Takeda's entyvio sc and celltrion's remsima sc eu5 launches have benefitted from parent brand reputation, new clinical data, and covid-19 restraints, according to spherix global insights

Exton, pa., jan. 20, 2021 /prnewswire/ -- two 2020 european medical agency (ema) approvals, takeda's entyvio sc and celltrion healthcare's infliximab biosimilar, remsima sc, have captured notable shares among eu5 ibd patients, according to spherix's recent report, realtime dynamix™:...
TAK Ratings Summary
TAK Quant Ranking